학술논문
Impact of treatment and clinical characteristics on the survival of children with medulloblastoma in Mexico
Document Type
article
Author
Violeta Salceda-Rivera; Isidoro Tejocote-Romero; Diana S. Osorio; Rosalba Bellido-Magaña; Araceli López-Facundo; Susana E. Anaya-Aguirre; Daniel Ortiz-Morales; Roberto Rivera-Luna; Evelyne Reyes-Gutiérrez; Rebeca Rivera-Gómez; Liliana Velasco-Hidalgo; Deyanira Cortés-Alva; Sandra Lagarda-Arrechea; Farina E. Arreguín-González; Alma E. Benito-Reséndiz; Silvia Chávez-Gallegos; Eloy Pérez-Rivera; Guillermo J. Gaytán-Fernández; José A. León-Espitia; Jociela Domínguez-Sánchez; Carlos Leal-Cavazos; Citlalli Simón-González; Tania C. Larios-Farak; Nubia A. Macías-García; Ana C. García-Espinosa; Francisco Guerrero-Maymes; Paola Casillas-Toral; Oscar González-Ramella
Source
Frontiers in Oncology, Vol 14 (2024)
Subject
Language
English
ISSN
2234-943X
Abstract
IntroductionData on medulloblastoma outcomes and experiences in low- and middle-income countries, especially in Latin America, is limited. This study examines challenges in Mexico’s healthcare system, focusing on assessing outcomes for children with medulloblastoma in a tertiary care setting.MethodsA retrospective analysis was conducted, involving 284 patients treated at 21 pediatric oncology centers in Mexico.ResultsHigh-risk patients exhibited markedly lower event-free survival than standard-risk patients (43.5% vs. 78.3%, p1.5cm², and lower radiotherapy doses significantly impacted event-free survival (EFS) and overall survival (OS). Platinum-based chemotherapy showed better results compared to the ICE protocol in terms of OS and EFS, which was associated with higher toxicity. Patients under 3 years old displayed notably lower OS and EFS compared to older children (36.1% vs. 55.9%, p=0.01).